CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
Tildrakizumabdrug
Likely dose
Tildrakizumab 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04112810
NCT04112810Phase 2Completed
CompareCT.gov

A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Medical College of Wisconsin·interventional·Posted Oct 2, 2019·Updated Oct 21, 2025

In Brief

A Phase 2 clinical trial evaluating Tildrakizumab for Hematologic Malignancies. Completed, enrolled 51 participants across 1 site.

Detailed Summary

This is a phase 2 open-label trial designed to evaluate the efficacy of tildrakizumab in improving graft-versus-host disease (GVHD)-free relapse-free survival after myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Malignancies
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2, 2019
Enrollment StartMar 1, 2020
Primary CompletionJun 1, 2024
Study CompletionJun 17, 2024
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 6.8 years ago

Interventions

Tildrakizumabdrug

100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.